Impact of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on the Term Infant Gut Microbiome: A State of the Science Review

J Midwifery Womens Health. 2021 May;66(3):351-359. doi: 10.1111/jmwh.13245. Epub 2021 Jun 11.

Abstract

Since the implementation of screening and prophylaxis guidelines for group B streptococcus (GBS) in the early 1990s there has been considerable advancement in scientific knowledge about the gut microbiome and its role in both health and disease processes. Research assessing early influences during the development of the infant gut microbiome has advanced considerably in the last 15 years. It is now widely accepted that early introduction of antibiotics in infancy is associated with increased risk for illness later in life. Research on antibiotic administration to pregnant individuals during labor for GBS colonization and its potential impact on the developing gut microbiome of term infants is now emerging. Despite the growing body of evidence of the negative impact of antibiotics on the gut microbiome, the guidelines for GBS prophylaxis among pregnant individuals have not changed significantly since their inception in the 1990s. This state of the science review examines the association between intrapartum antibiotic administration and alterations in the gut microbiome of term infants born vaginally, specifically in relation to microbial composition; the occurrence of and effect on antibiotic resistance genes in the infant gut; and the factors that may compound or mitigate these effects.

Keywords: antibiotic resistance genes; dysbiosis; group B streptococcus; infant gut composition; infant microbiome; intrapartum antibiotic prophylaxis.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antibiotic Prophylaxis
  • Female
  • Gastrointestinal Microbiome*
  • Humans
  • Infant
  • Infectious Disease Transmission, Vertical / prevention & control
  • Parturition
  • Pregnancy
  • Pregnancy Complications, Infectious* / drug therapy
  • Pregnancy Complications, Infectious* / prevention & control
  • Streptococcal Infections* / drug therapy
  • Streptococcus agalactiae

Substances

  • Anti-Bacterial Agents